Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
about
Clinical use of crizotinib for the treatment of non-small cell lung cancerOther targeted drugs in melanomaPathways and therapeutic targets in melanomaCombined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Mutant HRAS as novel target for MEK and mTOR inhibitorsPrimary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeMicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibitionThe selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.The MAPK pathway as an apoptosis enhancer in melanoma.Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.Genetically engineered mouse models of PI3K signaling in breast cancer.Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphomaPharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy.Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics.IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaGenetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerCombined MEK and PI3K inhibition in a mouse model of pancreatic cancerA phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation.Empirical inference of circuitry and plasticity in a kinase signaling networkAdvances in small-molecule drug discovery for triple-negative breast cancer.NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implicationsHeat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat StressTargeting drivers of melanoma with synthetic small molecules and phytochemicals.Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaMolecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerTherapeutic interventions to disrupt the protein synthetic machinery in melanomaThe combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.Targeting mutant NRAS signaling pathways in melanoma.The management of early-stage and metastatic triple-negative breast cancer: a review.Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.Predicting drug responsiveness in human cancers using genetically engineered mice.Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
P2860
Q24630466-C63EDA92-7AC0-48B7-A5B0-4F49F89DD29CQ26775594-EB7ED390-B1B8-432A-A95B-5DB493730566Q26865736-657A157D-C43F-447D-9126-77A42AF00F51Q27852093-18FB7632-2FE2-4342-8BC1-386EB10046B0Q27853238-140F3DB2-D815-48DB-8DE5-532C6435FEAFQ27853295-B8308FB0-36F5-4FA4-BF79-4118E2797301Q30539640-4291D326-0280-4147-AC4F-A381ADDE80B2Q33591361-E4791577-24F2-4414-AC8C-E5E7C0A8D66CQ33742688-D06DCD28-3425-493A-8F93-69A6EF5D5BF6Q34104135-E917194F-99EC-4F55-AC95-7DB8EA6E8FADQ34223118-A68F99AA-E35E-4063-9AAD-8E201F5B3551Q34332175-9FF9F8C5-34AE-48C0-80AC-27904D244B20Q34644692-74BC6D9D-D56D-4EAD-87A1-8A8D5DF05D59Q34708283-C5512034-84A9-4E83-890B-7EE2570E1A6FQ35020412-DBE601A4-DB46-4506-BA82-8C4C792B9EE0Q35020913-38BB0CD6-04F1-4930-A7A0-2197023FB5B0Q35236736-F2F78ACA-8AB2-4603-927B-4AD28BE15E1EQ35374807-FE50BA85-56A9-4C73-8550-80BC282D2905Q35425222-DEC67B5D-4D2C-4574-9FEB-99ACC5C07F7FQ35564248-C76065F8-0521-44B4-B7C5-18288B09412CQ35657842-C490D0C7-BD78-4D11-835E-71F35A573F49Q35659511-B4747F92-1626-410E-A0D5-0437B06568BBQ35677661-27DE5F3D-7EAA-46C9-8725-07498217A000Q35775850-94936C1C-DEB8-4BFA-A9DB-7CA88378DBE5Q35796180-C9B9C016-5406-4A37-89FD-F51D6F54475CQ35818491-766D4EBA-0E91-4544-9ADA-0C29262EF72FQ36083348-530CCB25-E104-4438-A445-7752FF29D157Q36128222-0B390507-FE42-40B8-9207-2BFE2E85916DQ36141097-11BC0032-ED78-4AE8-A230-DA435359EDE9Q36291134-E00C540C-F575-46FC-9070-A4DD634F96CCQ36440214-3923B0F5-B9CF-423C-BCB2-EE354949F885Q36473355-E3073572-99F3-44FF-9938-79F2E229065EQ36546319-DA80D682-53AB-4A54-B0C7-3D9544459853Q36784065-4684710A-61A9-4E95-AF68-8687881BDA23Q36894808-A03561AC-803C-4A0E-A459-A31CB6F27BDBQ36902066-F0D53DE9-995D-4950-BDA7-EF5B0A468F19Q37080240-D6435305-9AD3-4C8C-A26B-2828480269B7Q37120418-5A2D8BCE-653F-45F7-809B-2133A50FEE56Q37187379-3EF8F59E-38E0-4F38-B756-BA85C30F2C28Q37349748-CB59AEFB-AD93-4CD9-8CE4-D610F4D98B7A
P2860
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 August 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined PI3K/mTOR and MEK inh ...... faithful murine cancer models
@en
Combined PI3K/mTOR and MEK inh ...... faithful murine cancer models.
@nl
type
label
Combined PI3K/mTOR and MEK inh ...... faithful murine cancer models
@en
Combined PI3K/mTOR and MEK inh ...... faithful murine cancer models.
@nl
prefLabel
Combined PI3K/mTOR and MEK inh ...... faithful murine cancer models
@en
Combined PI3K/mTOR and MEK inh ...... faithful murine cancer models.
@nl
P2093
P2860
P50
P1476
Combined PI3K/mTOR and MEK inh ...... faithful murine cancer models
@en
P2093
Adam D Pfefferle
Austin J Combest
David B Darr
Gary L Johnson
James S Duncan
Jerry E Usary
Martin C Whittle
Patrick J Roberts
Soren M Johnson
P2860
P304
P356
10.1158/1078-0432.CCR-12-0563
P407
P577
2012-08-07T00:00:00Z